- Home
- RNA
as 02-21-2025 4:00pm EST
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.7B | IPO Year: | 2020 |
| Target Price: | $65.80 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.73 - $56.00 | Next Earning Date: | 03-07-2025 |
| Revenue: | $10,117,000 | Revenue Growth: | -0.19% |
| Revenue Growth (this year): | -8.44% | Revenue Growth (next year): | -17.95% |
Stock Insider Trading Activity of Avidity Biosciences Inc. (RNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gallagher Kathleen P. | RNA | Chief Program Officer | Feb 3 '25 | Sell | $32.16 | 5,875 | $188,918.26 | 50,554 | |
| Boyce Sarah | RNA | President and CEO | Jan 21 '25 | Sell | $28.59 | 10,397 | $297,291.42 | 337,411 | |
| LEVIN ARTHUR A | RNA | Director | Jan 21 '25 | Sell | $28.60 | 1,872 | $53,536.77 | 12,958 | |
| MacLean Michael F | RNA | Chief Financial Officer | Jan 21 '25 | Sell | $28.59 | 3,287 | $93,985.36 | 104,655 | |
| Flanagan W. Michael | RNA | Chief Scientific Officer | Jan 21 '25 | Sell | $28.59 | 5,672 | $162,191.97 | 91,975 | |
| McCarthy Teresa | RNA | Chief Human Resources Officer | Jan 21 '25 | Sell | $28.59 | 2,959 | $84,611.50 | 106,129 | |
| Hughes Steven George | RNA | Chief Medical Officer | Jan 21 '25 | Sell | $28.59 | 3,947 | $112,856.48 | 84,460 | |
| Gallagher Kathleen P. | RNA | Chief Program Officer | Jan 21 '25 | Sell | $28.98 | 9,411 | $277,912.09 | 50,554 | |
| Boyce Sarah | RNA | President and CEO | Dec 18 '24 | Sell | $32.66 | 31,855 | $1,040,384.30 | 337,411 | |
| MacLean Michael F | RNA | Chief Financial Officer | Dec 18 '24 | Sell | $32.66 | 11,151 | $364,191.66 | 104,655 |
Latest Avidity Biosciences Inc. News
RNA Breaking Stock News: Dive into RNA Ticker-Specific Updates for Smart Investing
Simply Wall St.
24 days ago
We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely
PR Newswire
a month ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Insider Monkey
a month ago
Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential
PR Newswire
a month ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
Avidity Biosciences Plans to Submit First Biologics License Application This Year
PR Newswire
a month ago
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025
Insider Monkey
2 months ago
Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?
PR Newswire
2 months ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare RNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNA Avidity Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.